for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bavarian Nordic A/S

BAVA.CO

Latest Trade

170.60DKK

Change

-4.30(-2.46%)

Volume

51,628

Today's Range

170.50

 - 

173.80

52 Week Range

103.20

 - 

225.00

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
174.90
Open
173.80
Volume
51,628
3M AVG Volume
7.86
Today's High
173.80
Today's Low
170.50
52 Week High
225.00
52 Week Low
103.20
Shares Out (MIL)
58.41
Market Cap (MIL)
10,246.30
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Bavarian Nordic A/S Earnings Call

Latest Developments

More

Bavarian Nordic Q2 EBITDA Turns To Profit Of DKK 197 Million

Bavarian Nordic Announces Positive Topline Results From Phase 3 Clinical Study Of Freeze-Dried Smallpox Vaccine

ExpreS2ion's Joint Venture AdaptVac Signs Final License Agreement With Bavarian Nordic On COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bavarian Nordic A/S

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Industry

Biotechnology & Drugs

Contact Info

Hejreskovvej 10A

3490

Denmark

+45.33.268383

http://www.bavarian-nordic.com

Executive Leadership

Gerard W. M. van Odijk

Independent Chairman of the Board

Paul John Chaplin

President, Chief Executive Officer

Anders Gersel Pedersen

Independent Deputy Chairman of the Board

Henrik Juuel

Executive Vice President, Chief Financial Officer

Henrik Birk

Executive Vice President, Chief Operating Officer

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2017

1.4K

2018

0.5K

2019

0.7K

2020(E)

2.0K
EPS (DKK)

2017

4.509

2018

-8.860

2019

-8.464

2020(E)

8.956
Price To Earnings (TTM)
15.63
Price To Sales (TTM)
6.83
Price To Book (MRQ)
1.95
Price To Cash Flow (TTM)
15.11
Total Debt To Equity (MRQ)
69.30
LT Debt To Equity (MRQ)
62.01
Return on Investment (TTM)
8.79
Return on Equity (TTM)
8.07

Latest News

Latest News

BRIEF-Expres2ion Biotech Holding Updates On Negotiations With Bavarian Nordic

* EXPRES2ION PROVIDES UPDATE ON NEGOTIATIONS WITH BAVARIAN NORDIC AND PROGRESS TOWARDS CLINICAL PHASE I/IIA TRIAL

BRIEF-Bavarian Nordic Announces European Marketing Authorization For Ebola Vaccine

* REG-BAVARIAN NORDIC ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR EBOLA VACCINE

BRIEF-Bavarian Nordic And Valneva Announce Partnership

* REG-BAVARIAN NORDIC AND VALNEVA ANNOUNCE MARKETING AND DISTRIBUTION PARTNERSHIP

BRIEF-Bavarian Nordic To Manufacture Additional Ebola Vaccines For Janssen

* REG-BAVARIAN NORDIC TO MANUFACTURE ADDITIONAL EBOLA VACCINES FOR JANSSEN

BRIEF-Bavarian Nordic Announces Topline Results From Phase 1 Clinical Trial Of Equine Encephalitis Virus Vaccine

* REG-BAVARIAN NORDIC ANNOUNCES TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF EQUINE ENCEPHALITIS VIRUS VACCINE

BRIEF-Bavarian Nordic Q1 EBITDA Turns To Profit Of DKK 641 Mln

* REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST THREE MONTHS OF 2020

BRIEF-Expres2ion Announces Bavarian Nordic Enters Agreement

* EXPRES2ION ANNOUNCES BAVARIAN NORDIC ENTERS AGREEMENT WITH ADAPTVAC TO ADVANCE THE COVID-19 VACCINE PROGRAM

BRIEF-Bavarian Nordic Enters Agreement With AdaptVac To Advance COVID-19 Vaccine Program

* BAVARIAN NORDIC ENTERS AGREEMENT WITH ADAPTVAC TO ADVANCE COVID-19 VACCINE PROGRAM

BRIEF-Bavarian Nordic Announces Major Shareholder Notification From Citigroup

* REG-BAVARIAN NORDIC ANNOUNCES MAJOR SHAREHOLDER NOTIFICATION FROM CITIGROUP INC

BRIEF-ATP Increases Its Ownership In Bavarian Nordic To 11.12% Of Share Capital

* REG-BAVARIAN NORDIC ANNOUNCES MAJOR SHAREHOLDER NOTIFICATION FROM ATP

BRIEF-Bavarian Nordic Announces Result Of Rights Issue

* ANNOUNCES RESULT OF OFFERING OF 25,911,252 NEW SHARES WITH PREEMPTIVE RIGHTS FOR COMPANY'S EXISTING SHAREHOLDERS AT A RATIO OF 4:5 AND A SUBSCRIPTION PRICE OF DKK 109 PURSUANT TO PROSPECTUS DATED MARCH 6, 2020

BRIEF-Bavarian Nordic: Board Member Erik Gregers Hansen Buys 17,600 Co's Shares

* REPORT OF TRANSACTIONS OF SHARES AND RELATED SECURITIES OF BAVARIAN NORDIC BY PERSONS HOLDING MANAGERIAL RESPONSIBILITIES AND/OR PERSONS/COMPANIES CLOSELY ASSOCIATED WITH SUCH

BRIEF-Bavarian Nordic FY EBIT Loss Narrows To DKK 328.4 Million

* ACQUISITION OF RABIPUR/RABAVERT AND ENCEPUR WILL HAVE A SIGNIFICANT POSITIVE IMPACT ON BAVARIAN NORDIC'S REVENUE, AS VACCINES WILL BECOME PRIMARY REVENUE DRIVER

GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments

GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.

FDA approves Bavarian Nordic's monkeypox vaccine

The U.S. Food and Administration on Tuesday approved Danish drugmaker Bavarian Nordic's Jynneos, making it the first approved vaccine for preventing monkeypox disease.

BRIEF-Bavarian Nordic REPORTS Positive Result From Phase 2 Trial Evaluating BN-Brachyury In Chordoma

* REPORTED ON WEDNESDAY POSITIVE RESULT FROM ONGOING PHASE 2 TRIAL EVALUATING BN-BRACHYURY IN CHORDOMA

BRIEF-Bavarian Nordic FY EBIT Rises To DKK 353.2 Million

* FY EBIT DKK 353.2 MILLION VERSUS DKK 33.0 MILLION YEAR AGO

BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer

* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab

* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up